EMA bans antibiotic APIs produced by drugmaker in China

Flag of China
The European Medicines Agency has cited an API maker in China, for not having good quality-control processes.

European authorities have decided to block the amoxicillin trihydrate API produced by a company in China, whose manufacturing quality oversight has been found to be weak.

The steps against Inner Mongolia Changsheng Pharmaceutical followed an October inspection of its plant in Tuoketuo, Hohhot, Inner Mongolia in China by Belgium inspectors, according to a post on the European Medicines Agency's (EMA) Eudra site. The Inner Mongolia Autonomous Region, borders Mongolia.

Inspectors listed one critical and eight major deficiencies. The critical deficiency was tied to the QA system, which inspectors called “weak” and incapable of establishing acceptable standards across the whole spectrum of processes. They specifically noted oversight of deviations, quality control, validation, complaint management and documentation, among others.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The EMA is suggesting that countries ban the company from shipping products unless producers have no alternative suppliers for the APIs. In that case, any shipped products should at least be retested, the EMA said.

RELATED: Lost in translation, FDA slaps Chinese drugmaker with warning letter for mixing up APIs

Both U.S. and European authorities have stepped up oversight of Chinese companies as more are found shipping ingredients to the West. Last fall, the FDA banned products and slapped a warning letter on China’s Guangdong Zhanjiang Jimin Pharmaceutical after an inspection found it had shipped multiple lots of an OTC product to the U.S. containing the wrong API because the company messed up a translation.

Suggested Articles

AZ and Daiichi reported "impressive" data for DS-8201. J&J and Legend's CAR-T showed promise in multiple myeloma. South Korea jailed Samsung…

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

With a green light in lung cancer, AstraZeneca's Imfinzi has become the first PD-L1 drug approved in China, ahead of Roche's Tecentriq.